What patient-reported outcomes (PROs) measured lurbinectedin’s delayed effects?
The information provided does not specify which patient-reported outcome measure(s) were used to assess lurbinectedin’s delayed effects, nor does it name any PRO instrument(s) (such as fatigue scales, pain scales, or quality-of-life tools) tied to delayed onsets or durability.
Where delayed effects are usually captured in PRO endpoints (so you can find the right measure)
In oncology trials, “delayed effects” are typically captured by PRO endpoints that track symptoms or functioning over time (for example, time to symptom worsening, duration of response, or longitudinal change from baseline). The exact PRO measure depends on the study protocol and could vary by indication (e.g., small-cell lung cancer vs. other settings) and by trial design.
What I need to answer precisely
If you share the trial name (or NCT number), indication, or the study report/table you’re looking at (e.g., “PROs analyzed in the delayed period” or the endpoint definitions), I can pinpoint the exact PRO measure(s) used to quantify delayed effects.
Sources
No sources were provided.